New Alzheimers trial ...

[Guest guest]

wonder if this would work on ASD too ...

Souvenaid is a treatment for Alzheimer's disease developed by Danone research

consisting of a cocktail of nutrients including uridine monophosphate, choline,

the omega-3 fatty acids EPA and DHA, phospholipids, B vitamins and antioxidants.

The results of its first clinical trials were announced at the Alzheimer's

Association International Conference on Alzheimer's Disease (ICAD) in July

2008.[1]

The basic ideas behind this treatment were developed by Prof. Wurtman of

M.I.T.

A cocktail to remember? Nutrient elixir shows promise against Alzheimer's

January 7, 2010 | 5:04 pm

Souvenaid sounds like a cool drink to be sipped while reading Proust in the

garden. But new research suggests that the cocktail of nutrients soon to be

marketed under that name may boost the production of brain cells lost in

Alzheimer's and slow the loss of verbal memory in the disease's early stages.

A study published Thursday in the journal Alzheimer's and Dementia found that

among 225 subjects diagnosed with early Alzheimer's disease, those who drank the

nutrient cocktail twice a day for 12 weeks improved their performance on tests

of verbal memory compared with newly diagnosed subjects who got a placebo drink.

The study is the first to suggest that a " medical food " might be effective in

stemming -- and perhaps reversing -- the cognitive tolls of Alzheimer's.

Souvenaid is expected to hit the American market in a test program as early as

this spring, marketed by the French giant Danone, maker of Dannon yogurt, and

its Nutricia subsidiary.

The nutrient cocktail emerged from research conducted by Dr. Wurtman, a

neuropharmacologist and physician at the Massachusetts Institute of Technology.

It contains a mix of nutrients all found in breast milk, and which are either

produced naturally by the body or ingested in foods. Earlier research had found

that the mix of nutrients -- uridine, choline and Omega-3 polyunsaturated fatty

acids -- " synergistically " boosts the volume of proteins in the brain that give

rise to synapses -- the branching structures that pass electrical impulses from

cell to cell in the brain.

The loss of synapses -- particularly in the hippocampal region, which is key to

memory formation -- is one of several hallmarks of Alzheimer's disease. Wurtman

said in an interview that if a mix of nutrients that so far have shown no side

effects could stem or reverse that synamptic loss, it could become a valuable

weapon in future physicians' arsenal against Alzheimer's.

Nigel , head of Nutricia's North American unit, said in an interview that

three other clinical trials are underway to test the effectiveness and safety of

Souvenaid, and that a full market roll-out could begin in the U.S. by next year.

Though the proposed Alzheimer's cocktail, as a dietary supplement, does not need

approval by the Food and Drug Administration before it can be marketed,

said the company " is adopting the principles you would adopt for going to market

with a pharmaceutical product, " including clinical evidence that it works. As a

" medical food, " said the company anticipates that Souvenaid would be

" taken under medical supervision. "

Will Souvenaid become a voguish cocktail for aging smarties keen to hold off the

cognitive decline that comes with age? Already, the Alzheimer's drug donepezil

(marketed as Aricept) has been tested as a cognitive enhancement drug, and some

consider taking it to be worth the risk. (The FDA, however, has pointedly

declined to approve Aricept's marketing even for mild cognitive impairment, a

loss of memory that is more serious than normal decline, but which leads

frequently to Alzheimer's.)

One of the three large trials underway will test Souvenaid on European subjects

with mild cognitive impairment. If that trial shows success, you can bet that

the cocktail may be the next big thing among the middle-aged smart set.